Lyncbio
1 known investors
Lync Bio develops next-generation antibody-drug conjugate (ADC) therapeutics using target-biology-driven and computational design of carriers, conjugates, linkers, and payloads. Its two proprietary technology platforms focus on disease areas including intestinal inflammation, multiple sclerosis, pan-cancer solid tumors, and multiple myeloma.
Investors · 1
Frequently asked questions
- What does Lyncbio do?
- Lync Bio develops next-generation antibody-drug conjugate (ADC) therapeutics using target-biology-driven and computational design of carriers, conjugates, linkers, and payloads. Its two proprietary technology platforms focus on disease areas including intestinal inflammation, multiple sclerosis, pan-cancer solid tumors, and multiple myeloma.
- Who are Lyncbio's investors?
- Lyncbio's investors include Pan-Lin Capital.